Program to Optimize Cancer Drug Trials
NoRD Bio's team of experts in tumor heterogeneity and evolution assessment has launched a program to aid pharma and biotech companies in cancer drug development.
"Running cancer drug trials without vision into individual tumor heterogeneity and evolution can compromise measurable drug response. We are excited to fill this gap with proven, cost efficient analysis."
Comprehensive Research Solutions
Cancer Research Support
Comprehensive bioinformatics and molecular analysis to understand cancer mechanisms, identify targets, and develop new treatments.
- Molecular mechanism discovery
- Heterogeneity and microenvironment analysis
- Mutation and evolution tracking
- Target and biomarker discovery
Drug Development
Accelerate drug development with cutting-edge omics data analysis for target discovery, validation, and biomarker identification.
- Target discovery and validation
- Preclinical development support
- Mechanism of action studies
- Biomarker discovery for patient stratification
NGS Assays Support All Development Stages
From basic research to clinical trials, our comprehensive solutions accelerate every phase of drug development.
Basic Research
Fundamental studies of disease molecular and cellular biology to enable rational drug discovery.
Target Discovery
Data-driven identification of biomolecules for treatment targets using genomic and proteomic data.
Target Validation
Gene expression analysis in knockout models to reveal desired and undesirable downstream effects.
Preclinical Development
Mechanism-of-action and off-target analysis using transcriptomics, epigenomics, and proteomics.
Biomarker Discovery
Identify markers to stratify patients by treatment response in pre-clinical and clinical settings.
Clinical Trials
MRD monitoring, patient selection, and response measurement to optimize trial outcomes.
Minimal Residual Disease (MRD) Monitoring
Cell-free tumor load measuring helps fill an unmet clinical need for real-time, noninvasive detection of tumor response to targeted therapies prior to radiographic assessment.
FDA Guidance on MRD
The US FDA finalized guidance in May 2022 to help sponsors use minimal residual disease (MRD) as a biomarker in clinical trials for hematologic malignancies, highlighting technology that can detect persistence of malignancy at orders of magnitude below conventional morphologic detection.
Trial Patient Selection
Use ctDNA as a marker of MRD to enrich trials for patients with higher-risk disease and increased events of recurrence or death.
Early Endpoint
Changes in ctDNA response to drugs have potential as early endpoints to support drug approval in early-stage cancer.